ES2065698T3 - Autobioticos y su utilizacion para eliminar in vivo celulas extrañas. - Google Patents

Autobioticos y su utilizacion para eliminar in vivo celulas extrañas.

Info

Publication number
ES2065698T3
ES2065698T3 ES91913184T ES91913184T ES2065698T3 ES 2065698 T3 ES2065698 T3 ES 2065698T3 ES 91913184 T ES91913184 T ES 91913184T ES 91913184 T ES91913184 T ES 91913184T ES 2065698 T3 ES2065698 T3 ES 2065698T3
Authority
ES
Spain
Prior art keywords
autobiotics
cells
vivo
latentiated
strange
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91913184T
Other languages
English (en)
Inventor
Laszlo G Egyud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cell Research Corp
Original Assignee
Cell Research Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Research Corp filed Critical Cell Research Corp
Application granted granted Critical
Publication of ES2065698T3 publication Critical patent/ES2065698T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE DESCRIBEN ANTIBIOTICOS CON CARACTERISTICAS DE LATENCIA FISICA Y QUIMICA. LOS ANTIBIOTICOS LATENTES SON UTILES PARA EL TRATAMIENTO O PREVENCION DE CUALQUIER ENFERMEDAD O CONDICION QUE RESULTE DE LA PRESENCIA DE CELULAS NO PURAS EN ANFITRIONES VERTEBRADOS. LOS ANTIBIOTICOS LATENTES SON UTILES ADEMAS EN LA SUPRESION DE LOS PROCESOS DE RECHAZO INMUNE, COMO RADIOSENSIBILIZADORES Y COMO ANTICOAGULANTES.
ES91913184T 1990-07-03 1991-07-01 Autobioticos y su utilizacion para eliminar in vivo celulas extrañas. Expired - Lifetime ES2065698T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/547,983 US5147652A (en) 1990-07-03 1990-07-03 Autobiotics and their use in eliminating nonself cells in vivo

Publications (1)

Publication Number Publication Date
ES2065698T3 true ES2065698T3 (es) 1995-02-16

Family

ID=24186953

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91913184T Expired - Lifetime ES2065698T3 (es) 1990-07-03 1991-07-01 Autobioticos y su utilizacion para eliminar in vivo celulas extrañas.

Country Status (9)

Country Link
US (1) US5147652A (es)
EP (1) EP0537267B1 (es)
JP (1) JPH06501680A (es)
AT (1) ATE112161T1 (es)
AU (1) AU8216691A (es)
CA (1) CA2086513A1 (es)
DE (1) DE69104362T2 (es)
ES (1) ES2065698T3 (es)
WO (1) WO1992000727A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260341A (en) * 1992-07-14 1993-11-09 Agro-K Corporation Inc. Product and process for treating bovine mastitis and bovine metritis
AU723585B2 (en) * 1996-03-28 2000-08-31 Trustees Of Boston University Methods of modulating melanin synthesis
US6033719A (en) * 1996-04-25 2000-03-07 Medtronic, Inc. Method for covalent attachment of biomolecules to surfaces of medical devices
US6331286B1 (en) 1998-12-21 2001-12-18 Photogen, Inc. Methods for high energy phototherapeutics
US8974363B2 (en) * 1997-12-11 2015-03-10 Provectus Pharmatech, Inc. Topical medicaments and methods for photodynamic treatment of disease
US8557298B2 (en) * 1998-08-06 2013-10-15 Provectus Pharmatech, Inc. Medicaments for chemotherapeutic treatment of disease
US20090117199A1 (en) * 1998-08-06 2009-05-07 Scott Timothy C Method of treatment of cancer
US20020001567A1 (en) * 1998-12-21 2002-01-03 Photogen, Inc. Intracorporeal medicaments for high energy phototherapeutic treatment of disease
US8470296B2 (en) * 1998-12-21 2013-06-25 Provectus Pharmatech, Inc. Intracorporeal medicaments for high energy phototherapeutic treatment of disease
US7384623B1 (en) 1998-12-21 2008-06-10 Provectus Pharmatech, Inc. High energy phototherapeutic agents
IT1318424B1 (it) * 2000-03-24 2003-08-25 Unihart Corp Composti con attivita' anti-hiv.
US6596755B2 (en) * 2001-07-02 2003-07-22 Dabur Research Foundation Oral formulation of methylglyoxal and its imino acid conjugates for human use
GB0125659D0 (en) * 2001-10-25 2001-12-19 Ssl Int Plc Spermicides
US20040225077A1 (en) 2002-12-30 2004-11-11 Angiotech International Ag Drug delivery from rapid gelling polymer composition
AU2004209644A1 (en) * 2003-02-03 2004-08-19 Palo Alto Institute Of Molecular Medicine Cell-killing molecules and methods of use thereof
US20040171175A1 (en) * 2003-02-28 2004-09-02 Swanson Basil I. Process for conjugating biomolecules to hydrophobic membrane-incorporated molecules
EP3204043B1 (en) 2014-10-07 2023-06-07 Kinsella, Timothy J. METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER WITH 5-IODO-2-PYRIMIDINONE-2'-DEOXYRIBOSE (IPdR)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4066650A (en) * 1971-02-11 1978-01-03 Egyud Laszlo G Keto-aldehyde-amine addition products and method of making same
US4529561A (en) * 1978-03-24 1985-07-16 The Regents Of The University Of California Method for producing liposomes in selected size range
US4241046A (en) * 1978-11-30 1980-12-23 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4440740A (en) * 1982-04-26 1984-04-03 Merck & Co., Inc. α-Keto aldehydes as enhancing agents of gastro-intestinal drug absorption
DE3218121A1 (de) * 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
US4861588A (en) * 1985-02-05 1989-08-29 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
CA1270198A (en) * 1984-08-08 1990-06-12 Marcel B. Bally Encapsulation of antineoplastic agents in liposomes
ES2039203T3 (es) * 1985-11-22 1993-09-16 Takeda Chemical Industries, Ltd. Composicion de liposomas.
JPH0825869B2 (ja) * 1987-02-09 1996-03-13 株式会社ビタミン研究所 抗腫瘍剤包埋リポソ−ム製剤

Also Published As

Publication number Publication date
AU8216691A (en) 1992-02-04
DE69104362T2 (de) 1995-05-18
DE69104362D1 (de) 1994-11-03
ATE112161T1 (de) 1994-10-15
JPH06501680A (ja) 1994-02-24
US5147652A (en) 1992-09-15
CA2086513A1 (en) 1992-01-04
EP0537267B1 (en) 1994-09-28
WO1992000727A1 (en) 1992-01-23
EP0537267A1 (en) 1993-04-21

Similar Documents

Publication Publication Date Title
ATE112161T1 (de) Autobiotika sowie deren verwendung bei der in vivo eliminierung körperfremder zellen.
MX9101869A (es) Ciclosporinas, composicion farmaceutica que las contiene y procedimiento para la produccion de las mismas
MX9101046A (es) Anticuerpos novedosos para el tratamiento y prevencion de infeccion de animales y el hombre
IT1293690B1 (it) Stent per angioplastica, particolarmente per il trattamento di lesioni aorto-ostiali ed ostiali.
IT1240078B (it) Procedimento di trattamento di polveri inorganiche.
ATE165511T1 (de) Behandlung von organtransplantatsabstossung
TR199801110A3 (tr) Gögüs nakillerinde kapsüler büzülme tedavisi için ekipman
MX9100352A (es) Procedimiento para la recuperacion de valores de titanio
DE69000510D1 (de) Zusammensetzung fuer die behandlung von wasser oder waesserigen systemen.
EA200300849A1 (ru) Способы лечения или профилактики кожных заболеваний с помощью cd2-связывающих агентов
FI951511L (fi) IL-10:n käyttö insuliinista riippuvan diabetes mellituksen ennaltaestoon tai hoitoon
ES2103825T3 (es) Composiciones farmaceuticas que contienen 5-difluorometoxi-2-(3,4-dimetoxi-2-piridil)-metilsulfinil)bencimidazol y un agente anti-helicobacter para el tratamiento de trastornos gastrointestinales.
NO921993D0 (no) Fremgangsmaate for efterbehandling av amfotaere eller zwitterioniske tensider
DE59106803D1 (de) Substituierte Pyrido-oxazine.
PT97277A (pt) Processo para a preparacao de formulacoes farmaceuticas, contendo, por exemplo, ciclosporina a e factor de veneno de cobracapelo, uteis para a inibicao da rejeicao de aloenxerto e de xenoenxerto concordante
IT1213210B (it) Procedimento per il trattamento e/o l'immagazzinamento di residui industriali.
ES2061775T3 (es) Derivados de estrobirulina, su obtencion y empleo.
DE69023331D1 (de) Behandeltes hämoglobin und dessen herstellung.
ES2055421T3 (es) Uso de clormetiazol en la fabricacion de un medicamento para la prevencion y/o el tratamiento de neurodegeneracion.
ES2018613B3 (es) Procedimiento y dispositivo para la depuracion de aguas contaminadas.
ES1011387Y (es) Protesis para el tratamiento y recuperacion de miembros inferiores.
NO910062L (no) Pose for brukte engangsartikler som er benyttet ved kirurgiske operasjoner, saasom operasjonsduker og kompresser.
DE3787493D1 (de) Lederbehandlungsmittel.
DE58908686D1 (de) Lederbehandlungsmittel.
TR24994A (tr) Pamuk yapraklarinin giderilmesine mahsus madde.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 537267

Country of ref document: ES